Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
November 14th 2022Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Read More
NCPA CEO: Express Scripts Is Limiting, Restricting Veterans’ Access to Health Care
November 11th 2022This Veteran’s Day, NCPA CEO B. Douglas Hoey, PharmD, MBA, discusses the implications of Express Scripts’ elimination of the pharmacy of choice option for TRICARE beneficiaries in their contract with the Department of Defense.
Watch
Review of the 2022 ACCE Guidelines for Non-Alcoholic Fatty Liver Disease
November 10th 2022The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.
Read More